Beyond targeted

Tango Therapeutics is a biotechnology company developing novel therapies targeting context-dependent vulnerabilities in cancers. Tango’s robust product engine is designed to support the discovery and development of breakthrough medicines that provide deeper, more sustained benefit than today’s targeted therapies, and that extend the benefits of available immuno-oncology agents. The company’s programs are focused in the area of synthetic lethality, the interaction between two genes that causes cell death when both are inactivated.

Year Invested: 2017
Location: Cambridge, Mass.

Recent News

May 9, 2018
Tango Therapeutics Bolsters Expertise in Oncology Translational Research and Clinical Pharmacology with Leadership Expansion

March 8, 2018
Tango Therapeutics Expands Board of Directors with the Addition of Leading Oncology Experts with Deep Experience in Targeted and Personalized Therapies

December 6, 2017
Tango Therapeutics Announces the Addition of Shakti Narayan, Ph.D., J.D. as Chief Business Officer

Read More News

Associated Team Members

Cary Pfeffer, M.D.

Alexis Borisy

Barbara Weber, M.D.
Venture Partner